Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019063580) HUMAN SOLUBLE CD146 PROTEINS, PREPARATION AND USES THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/063580 International Application No.: PCT/EP2018/076046
Publication Date: 04.04.2019 International Filing Date: 26.09.2018
IPC:
C07K 14/705 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
705
Receptors; Cell surface antigens; Cell surface determinants
Applicants:
UNIVERSITE D'AIX-MARSEILLE [FR/FR]; 58 boulevard Charles Livon 13007 MARSEILLE, FR
ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE [FR/FR]; 80 rue Brochier 13005 MARSEILLE, FR
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) [FR/FR]; 101 rue de Tolbiac 75013 PARIS, FR
Inventors:
BLOT-CHABAUD, Marcel; FR
NOLLET, Marie; FR
BACHELIER, Richard; FR
BARDIN, Nathalie; FR
DIGNAT-GEORGE, Françoise; FR
Agent:
CABINET BECKER ET ASSOCIES; 25, rue Louis le Grand 75002 PARIS, FR
Priority Data:
17306271.226.09.2017EP
Title (EN) HUMAN SOLUBLE CD146 PROTEINS, PREPARATION AND USES THEREOF
(FR) PROTÉINES CD146 SOLUBLES HUMAINES, PRÉPARATION ET UTILISATIONS ASSOCIÉES
Abstract:
(EN) The present invention relates to compositions and methods for modulating angiogenesis in vivo, ex vivo or in vitro. More particularly, the invention relates to new soluble CD146 proteins usable in the context of human therapy, as well as to corresponding antibodies. The invention also relates to compositions comprising such compounds, particularly pharmaceutical or diagnostic compositions, including kits and the like, as well as methods of therapy or diagnosis using said compounds, compositions and cells.
(FR) La présente invention concerne des compositions et des procédés de modulation de l'angiogenèse in vivo, ex vivo ou in vitro. Plus particulièrement, l'invention concerne de nouvelles protéines CD146 solubles utilisables dans le contexte d'une thérapie humaine, ainsi que des anticorps correspondants. L'invention concerne également des compositions comprenant de tels composés, en particulier des compositions pharmaceutiques ou diagnostiques, y compris des kits et similaires, ainsi que des procédés thérapeutiques ou diagnostiques mettant en œuvre lesdits composés, lesdites compositions et lesdites cellules.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)